Board of Directors

Alligator Bioscience is governed by a diverse and experienced Board of Directors, combining scientific, industry, and strategic expertise. The Chair and board members are committed to oversight of our clinical-stage pipeline, corporate governance, and long-term value creation as we advance CD40-targeted immuno-oncology therapies from Lund, Sweden.

Hans-Peter Ostler

Chairman of the Board

• Board member since: 2021
• Independent in relation to the Company and its management: Yes
• Independent in relation to major shareholders: No
• Holdings in Alligator: 47,366 shares, 100,000 warrants in program TO 2022/2025 II, 240,000 warrants in program TO 2023/2026 II, 160,000 warrants in program TO 2024/2027 II, 46,912,890 warrants in program TO 12 and 23,456,445 warrants in program TO 13.
• Other current positions: Chairman of the Board in Hoodin AB and NH3 AB, board member of InorbitTX, Oblique Therapeutics AB, Encare AB and Lennart Ekerholms Stiftelse. Deputy board member in O Mgmt AB.

• Full profile

Denise Goode

Board member

• Board member since: 2022
• Independent in relation to the Company and its management: Yes
• Independent in relation to major shareholders: Yes
• Holdings in Alligator: 240,000 warrants in program TO 2023/2026 II and 160,000 warrants in program TO 2024/2027 II.
• Other current positions: CEO of QED Life Sciences Limited, a consultancy company advising and supporting the strategic direction of biotech companies and providing business mentoring to CEOs and senior leaders. Board member of Abliva AB (publ) where she is chair of the remuneration committee and a member of the audit committee. VP, Business Development at AnaMar AB. Certified COVID vaccinator for the UK National Health Service.

• Full profile

Eva Sjökvist Saers

Board member

• Board member since: 2021
• Independent in relation to the Company and its management: Yes
• Independent in relation to major shareholders: Yes
• Holdings in Alligator: 100,000 warrants in program TO 2022/2025 II, 240,000 warrants in program TO 2023/2026 II and 160,000 warrants in program TO 2024/2027 II.
• Other current positions: Chairman of the board of Dicot AB (publ) and Coegin Pharma AB. Board member of Apoex AB, Bluefish Pharmaceuticals AB (publ) and Oxcia AB. Deputy board member of Brainstorm Aktiebolag.

• Full profile

Karin Nordbladh

Employee representative

• Board member since: 2023
• Independent in relation to the Company and its management: No
• Independent in relation to major shareholders: Yes
• Holdings in Alligator: 610 shares, 180,000 warrants in program TO 2023/2026 I, 120,000 warrants in program TO 2024/2027 I, and 150,000 warrants in program TO 13.

• Full profile